Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations

Por T. Ziglioli, S. Cartella, C. Casu, A. Tincani, R. Cattaneo
Publicado em 2011-06-01

Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease

Por P.L. Meroni, F. Allegri, L. Andreoli, S. Piantoni, A. Tincani
Publicado em 2012-12-01

Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience

Por R. Cattaneo, M. Ferrari, S. Archetti, L. Andreoli, M. Taraborelli, A. Tincani
Publicado em 2011-06-01

Role of anti-prothrombin in antiphospholipid syndrome

Por M. Cinquini, M. Vianelli, F. Allegri, R. Cattaneo, G. Balestrieri, A. Tincani
Publicado em 2002-09-01

Polarization of TH2 response is decreased during pregnancy in systemic lupus erythematosus

Por A. Tincani, D. Villalta, M. Zen, A. Ghirardello, L. Iaccarino, L. Punzi, A. Doria
Publicado em 2012-12-01

Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?

Por A. Tincani, I. Cavazzana, A. Ceribelli, M. Fredi, F. Inverardi, M. Taraborelli, F. Franceschini
Publicado em 2012-12-01

The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus

Por M. Taraborelli, M.G. Lazzaroni, N. Martinazzi, M. Fredi, I. Cavazzana, F. Franceschini, A. Tincani
Publicado em 2016-12-01

Typing TREX1 gene in patients with systemic lupus erythematosus

Por M. Fredi, M. Bianchi, L. Andreoli, G. Greco, I. Olivieri, S. Orcesi, E. Fazzi, C. Cereda, A. Tincani
Publicado em 2015-06-01

Macrophage activation syndrome in adult systemic lupus erythematosus: report of seven adult cases from a single Italian rheumatology center

Por F. Dall'Ara, I. Cavazzana, M. Frassi, M. Taraborelli, M. Fredi, F. Franceschini, L. Andreoli, M. Rossi, C. Cattaneo, A. Tincani, P. Airò
Publicado em 2018-07-01

Subpopulations of anti-β2glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β2glycoprotein I

Por P.L. Meroni, T. Avcin, A. Lojacono, M. Frassi, M. Nuzzo, W.L. Binder, G.L. Norman, M. Motta, C. Nalli, L. Andreoli, A. Tincani
Publicado em 2011-06-01

P6.18 CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS; ARE THERE ANY DIFFERENCES?

Por A. Paini*, L. Andreoli, M. Salvetti, F. Dall’Ara, S. Piantoni, C. Donini, C. Agabiti Rosei, F. Bertacchini, D. Stassaldi, E. Agabiti Rosei, A. Tincani, M.L. Muiesan
Publicado em 2015-11-01

Fine specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1

Por P.L. Meroni, T. Avcin, V. Medeghini, A. Meini, A. Lojacono, M. Frassi, M. Nuzzo, Z. Shums, W.L. Binder, G.L. Norman, M. Motta, L. Andreoli, C. Nalli, A. Tincani
Publicado em 2011-09-01

3.5 EFFECT OF SHORT-TERM TREATMENT WITH LERCANIDIPINE ON CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND STRUCTURAL ALTERATIONS IN RETINAL ARTERIOLES

Por C. De Ciuceis, C. Rossini, E. La Boria, S. Duse, F. Semeraro, C. Agabiti Rosei, P. Airò, M. Scarsi, A. Tincani, M.L. Muiesan, A. Paini, M. Salvetti, E. Porteri, E. Agabiti Rosei, D. Rizzoni
Publicado em 2012-11-01

New EULAR guidelines about treatment systemic lupus eritematosus

Por G Bertsias, J Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I Gilboe, F Houssiau, T Huizinga, D Isenberg, C Kallenberg, M Khamashtau, J Piette, M Schneider, J Smolen, G Sturfelt, A Tincani, R van Vollenhoven, C Gordon, D Boumpas
Publicado em 2008-02-01